Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ozotel-AMH is a fixed-dose combination antihypertensive medication manufactured by Ozone Pharmaceuticals. It contains three active ingredients: telmisartan (40mg), amlodipine (5mg), and hydrochlorothiazide (12.5mg). Telmisartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral vasodilation. Hydrochlorothiazide is a thiazide diuretic that acts on the distal convoluted tubule to inhibit sodium and chloride resorption, thereby increasing water excretion and reducing plasma volume. This triple therapy is typically prescribed for patients whose blood pressure is not adequately controlled by dual therapy, helping to mitigate the risk of cardiovascular complications such as stroke and myocardial infarction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ozotel-AMH.